Latest news
Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030
Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%
Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation
Manufacturing expansion in the United States
Novartis is expanding our manufacturing and R&D facilities in the US to scale innovation, help patients and create jobs.
Bringing breakthroughs to more patients
At Novartis, we don’t just discover life-changing medicines, we're part of a broader effort to help ensure medicines reach the people who need them most, wherever they live, because the true value of innovation lies in its ability to improve lives.
Annual reporting suite
Explore and download our Annual Report 2025, Report on Nonfinancial Matters 2025 and other reporting documents.